Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL) Meeting Abstract
| Authors: | Locke, F. L.; Lekakis, L. J.; Eradat, H.; Munoz, J.; Tees, M. T.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S.; Popplewell, L.; Hamadani, M.; Oluwole, O. O.; Perales, M. A.; Miklos, D. B; Fisher, P.; Goyal, L.; Kaufman, G.; Kai, K.; Balakumaran, A.; Neelapu, S. S. |
| Abstract Title: | Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL) |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.2517 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 2517 -- This meeting was also held virtually -- Source: Cinahl |
